Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.


Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6% of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11% of normal) were required to reduce urinary GAG excretion; and high levels (>or=50% of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.

DOI: 10.1089/hum.2009.189
Citations per Year

174 Citations

Semantic Scholar estimates that this publication has 174 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Cotugno2010DifferentSE, title={Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.}, author={Gabriella Cotugno and Alessandra Tessitore and Anita Capalbo and Patrizia Annunziata and Caterina Strisciuglio and Armida Faella and Michela Aurilio and Maurizio Di Tommaso and Fabio Russo and Antonio Mancini and Elvira de Leonibus and Luigi Aloj and Alberto Auricchio}, journal={Human gene therapy}, year={2010}, volume={21 5}, pages={555-69} }